Novel Agents Targeting the Source of HCM DiseasePremiere Date: Wednesday, April 20, 2022
This activity offers CE credit for:%>
- ABIM (MOC)
- Medicine (accme)
- Nursing (ANCC)
- Pharmacy (acpe)
- PA (aapa)
All other clinicians will receive a Certificate of Attendance stating this activity was certified for AMA PRA Category 1 Credit™
Credit Expiration Date:
Thursday, April 20, 2023
Note: Credit Is No Longer Available
|Martin S. Maron, MD (Moderator)
Director, Hypertrophic Cardiomyopathy Center
Co-Director, Cardiac CT and MRI
Tufts University School of Medicine
|Harry Rakowski , MD, FRCP, FACC, FASE
Professor of Medicine
University of Toronto
Past Douglas Wigle Research Chair in HCM
Director, Hypertrophic Cardiomyopathy Clinic
Peter Munk Cardiac Centre
University Health Network
Hypertrophic cardiomyopathy (HCM) is prevalent around the world, with a conservatively estimated 20 million individuals affected. Even in developed countries, current management of HCM is suboptimal. Much has been learned over the past 2 decades about the pathophysiology of HCM and new therapies such as mavacamten, CK-274, IMB-101, and CT-G20 are currently being developed and tested in clinical trials addressing the underlying pathophysiology of HCM. Although these new agents are in late stages of development, clinicians are often not fully up to date on this progress and the potential opportunity to improve care for patients.
Please join Drs. Maron and Rakowski in this final installment of a CMEO Snack series on HCM as they discuss methods to assess study results of emerging HCM disease-specific treatments targeting cardiac myosin in order to optimize outcomes for patients.
At the end of this CE activity, participants should be able to:
- Assess study results of emerging HCM disease-specific treatments regarding cardiac myosin.
Supported by an educational grant from Bristol Myers Squibb.
Cardiologists, interventional cardiologists, electrophysiologists, cardiac surgeons (Secondary: Primary care physicians/General practitioners, PAs, nurse practitioners, nurses, and pharmacists)
Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 0.5 medical knowledge MOC points in the American Board of Internal Medicine's (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider's responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.
Through a mutual recognition agreement between the AMA and the UEMS-EACCME, European physicians completing an e-learning activity from a US-based ACCME-accredited CME provider can use AMA PRA Category 1 Credit™ toward their credit requirements. CME Outfitters is based in Radnor, Pennsylvania, USA. Please retain your certificate as proof of completion.
Royal College MOC:
Through an agreement between the Accreditation Council for Continuing Medical Education and the Royal College of Physicians and Surgeons of Canada, medical practitioners participating in the Royal College MOC Program may record completion of accredited activities registered under the ACCME’s “CME in Support of MOC” program in Section 3 of the Royal College’s MOC Program.
MIPS Improvement Activity:
This activity counts towards MIPS Improvement Activity requirements under the Medicare Access and CHIP Reauthorization Act of 2015 (MACRA). Clinicians should submit their improvement activities by attestation via the CMS Quality Payment Program website.
Dr. Maron reports the following financial relationships:
Advisory Board: Cytokenetics (REDWOOD-HCM Steering Committee)
Consultant: Imbria and Takeda Pharmaceuticals U.S.A., Inc.
Dr. Rakowski has no financial relationships to disclose.
The following peer reviewer and CME Outfitters staff have no financial relationships:
Faculty of this CE activity may include discussions of products or devices that are not currently labeled for use by the FDA. The faculty have been informed of their responsibility to disclose to the audience if they will be discussing off-label or investigational uses (any uses not approved by the FDA) of products or devices.
Questions about this activity? Call us at 877.CME.PROS (877.263.7767).